Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

Apogee Therapeutics CEO Michael Henderson disposed of 95,046 shares, with 75,046 gifted to charity and 20,000 sold under a pre-established trading plan. Henderson retains 921,000 shares worth ~$123 million. The insider activity is not viewed as a red flag given the CEO's substantial remaining stake. Apogee's lead antibody candidate showed strong Phase 2 data for atopic dermatitis, with Phase 3 trials and head-to-head comparisons against Dupixent expected in late 2026. The company has $1.3 billion in cash funding operations into 2029.

AbbVie, a Dividend King, is acquiring Apogee Therapeutics for $10.9 billion to strengthen its drug pipeline and maintain its dividend growth streak. The deal brings late-stage drug candidates like zumilokibart for atopic dermatitis and respiratory drugs, helping AbbVie replace revenue lost from Humira's patent expiration with newer products like Skyrizi and Rinvoq.

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting competing offers.

AbbVie announced a $10.9 billion acquisition of clinical-stage biotech Apogee Therapeutics, paying $135.11 per share in cash. The deal strengthens AbbVie's immunology portfolio with access to promising drug candidates like zumilokibart for eczema and asthma. While the acquisition will create near-term EPS headwinds, analysts expect it to be accretive by 2032 and support AbbVie's dividend yield of over 3%.

Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.

Apogee Therapeutics CEO Michael Thomas Henderson sold 20,000 shares (~$1.5 million) on March 11, 2026, representing 1.71% of his holdings. The sale was executed under a Rule 10b5-1 plan, suggesting it reflects a pre-planned strategy rather than negative sentiment. Despite the insider sale, the company's stock has surged nearly 100% in the past year. The article emphasizes that investors should focus on Apogee's positive Phase 2 clinical data showing 85% patient response durability, upcoming Phase 3 trials, and a $350 million equity offering that strengthens its balance sheet for late-stage development.

Apogee Therapeutics priced an underwritten public offering of 5 million shares at $70 per share, raising approximately $350 million in gross proceeds. The offering is expected to close on March 26, 2026. The company is a clinical-stage biotech firm developing novel biologics for inflammatory and immunology markets, with its lead program Zumilokibart (APG777) in development for atopic dermatitis, asthma, and eosinophilic esophagitis.

Apogee Therapeutics announced it will report 52-week Phase 2 APEX trial data for zumilokibart (APG777) in atopic dermatitis patients on March 23, 2026, via conference call at 8:00 a.m. ET. The company is advancing novel biologics targeting inflammatory and immunology markets.

Great Point Partners increased its stake in Apogee Therapeutics (APGE) by 70,000 shares to 374,000 shares worth $28.23 million, making it the fund's largest holding at 9.15% of assets. APGE stock has doubled over the past year and is advancing monoclonal antibody therapies for inflammatory diseases with Phase 2 atopic dermatitis data expected in H1 2026.

Apogee Therapeutics reported positive interim Phase 1b results for zumilokibart (APG777), its anti-IL-13 antibody, in mild-to-moderate asthma patients, demonstrating rapid and durable suppression of FeNO biomarker through 16 weeks with a favorable safety profile. The company also highlighted multiple anticipated 2026 milestones including Phase 2 APEX data readouts in atopic dermatitis and potential Phase 3 initiation by late 2026, with a strong cash position of $913 million supporting operations into H2 2028.

Apogee Therapeutics reported positive Phase 1 trial results for APG333, a novel half-life extended TSLP antibody, demonstrating a 55-day half-life and potential for quarterly dosing in respiratory treatments.